pilsicainide has been researched along with Cardiac Hypertrophy in 1 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakazato, Y | 1 |
| Nakata, Y | 1 |
1 other study available for pilsicainide and Cardiac Hypertrophy
| Article | Year |
|---|---|
Images in cardiology: Successful treatment of atrial tachycardia-induced cardiomyopathy with pilsicainide.
Topics: Adolescent; Anti-Arrhythmia Agents; Cardiomegaly; Female; Humans; Lidocaine; Radiography; Stroke Vol | 2001 |